The Anglo-Swedish drugmaker AstraZeneca submitted on Tuesday a request for emergency use of authorization (EUA) with the U.S. Food and Drug Administration (FDA) for its new treatment to prevent COVID-19.
In a statement on Tuesday, AstraZeneca said the new antibody therapy is for people who respond poorly to vaccines because of a weakened immune system, and that its file included data from a late-stage trial that showed its new therapy reduced the risk of people developing any COVID-19 symptoms by 77%.
AstraZeneca added that the antibody therapy called AZD7442 could also supplement a vaccination course for those who need to booster their protection further such as military personnel.
AstraZeneca also said that AZD7442 contained lab-made antibodies designed to stay longer in the body for months to contain the virus in case of an infection.
Reuters reported that COVID-19 therapies based on the same class of monoclonal antibodies were also being developed by rivals Regeneron, Eli Lilly, and GlaxoSmithKline with partner Vir, competing for a role in COVID-19 treatment prevention.
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.